SG11201905259SA - Preferred pairing of antibody domains - Google Patents
Preferred pairing of antibody domainsInfo
- Publication number
- SG11201905259SA SG11201905259SA SG11201905259SA SG11201905259SA SG11201905259SA SG 11201905259S A SG11201905259S A SG 11201905259SA SG 11201905259S A SG11201905259S A SG 11201905259SA SG 11201905259S A SG11201905259S A SG 11201905259SA SG 11201905259S A SG11201905259S A SG 11201905259SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- antibody
- domain
- domains
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 09 August 2018 (09.08.2018) WIP0 I PCT ill 1111u°11101llioIIl °nolo DID mil HE Elmo mnio oimIE (10) International Publication Number WO 2018/141894 Al (51) International Patent Classification: CO7K 16/28 (2006.01) (21) International Application Number: PCT/EP2018/052624 (22) International Filing Date: 02 February 2018 (02.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17154388.7 02 February 2017 (02.02.2017) EP (71) Applicant: MERCK PATENT GMBH [DE/DE]; Frank- furter StraBe 250, 64293 Darmstadt (DE). (72) Inventors: RUKER, Florian; Montigasse 6, 1170 Vien- na (AT). BONISCH, Maximilian; Boerhaavegasse 3/2/10, 1030 Vienna (AT). (74) Agent: REDL, Gerda et al.; REDL Life Science Patent At- torneys, Donau-City-StraBe 11, 1220 Vienna (AT). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). — Published: with international search report (Art. 21(3)) 00 (54) Title: PREFERRED PAIRING OF ANTIBODY DOMAINS 1-1 0, - -- 13 (57) : An antigen-binding molecule (ABM) comprising a cognate LC/HC dimer of an antibody light chain (LC) composed of a VL and a CL antibody domain, associated to an antibody heavy chain (HC) comprising at least a VH and a CH1 antibody domain, O which association is through pairing the VL and VH domains and the CL and CH domains, wherein the amino acids at the position 18 N in the CL domain and at the position 26 in the CH1 domain are of opposite polarity, wherein numbering is according to the IMGT.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17154388 | 2017-02-02 | ||
PCT/EP2018/052624 WO2018141894A1 (en) | 2017-02-02 | 2018-02-02 | Preferred pairing of antibody domains |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201905259SA true SG11201905259SA (en) | 2019-08-27 |
Family
ID=57965749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201905259SA SG11201905259SA (en) | 2017-02-02 | 2018-02-02 | Preferred pairing of antibody domains |
Country Status (13)
Country | Link |
---|---|
US (1) | US20190352429A1 (en) |
EP (1) | EP3577137A1 (en) |
JP (1) | JP7123063B2 (en) |
KR (1) | KR20190113870A (en) |
CN (1) | CN110382537B (en) |
AU (1) | AU2018214208A1 (en) |
BR (1) | BR112019013648A2 (en) |
CA (1) | CA3050988A1 (en) |
IL (1) | IL268401A (en) |
MX (1) | MX2019007984A (en) |
SG (1) | SG11201905259SA (en) |
WO (1) | WO2018141894A1 (en) |
ZA (1) | ZA201903796B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180069839A (en) | 2015-10-08 | 2018-06-25 | 자임워크스 인코포레이티드 | Antigen-binding polypeptide constructs including kappa and lambda light chains and uses thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
AU777192B2 (en) * | 1994-05-27 | 2004-10-07 | Ariad Gene Therapeutics, Inc. | Immunosuppressant target proteins |
ATE514717T1 (en) * | 2002-07-18 | 2011-07-15 | Merus B V | RECOMBINANT PRODUCTION OF ANTIBODIES MIXTURES |
SI1713503T1 (en) * | 2004-02-10 | 2013-12-31 | The Regents Of The University Of Colorado, A Body Corporate | Inhibition of factor b, the alternative complement pathway and methods related thereto |
CA2646965C (en) | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Engineered heterodimeric protein domains |
CA2693863C (en) | 2007-07-17 | 2017-10-03 | Merck Patent Gmbh | Engineered anti-alpha v- integrin hybrid antibodies |
CN101348475B (en) * | 2007-07-20 | 2011-03-30 | 重庆人本药物研究院 | Novel method for synthesizing orlistat, intermediate compound and preparation thereof |
AU2010252284A1 (en) | 2009-05-27 | 2011-11-17 | F. Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
JP6167040B2 (en) * | 2010-11-05 | 2017-07-19 | ザイムワークス,インコーポレイテッド | Design of stable heterodimeric antibodies with mutations in the Fc domain |
DK2773671T3 (en) * | 2011-11-04 | 2021-11-15 | Zymeworks Inc | DESIGN OF STABLE HETERODIMED ANTIBODY WITH MUTATIONS IN THE FC DOMAIN |
JP6203838B2 (en) * | 2012-06-27 | 2017-09-27 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Method for selecting and creating tailor-made highly selective and multispecific targeting entities comprising at least two different binding entities and uses thereof |
UY35148A (en) * | 2012-11-21 | 2014-05-30 | Amgen Inc | HETERODIMERIC IMMUNOGLOBULINS |
WO2014150973A1 (en) * | 2013-03-15 | 2014-09-25 | Eli Lilly And Company | Methods for producing fabs and bi-specific antibodies |
JP6904902B2 (en) * | 2014-12-05 | 2021-07-21 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Domain exchange antibody |
-
2018
- 2018-02-02 US US16/476,380 patent/US20190352429A1/en not_active Abandoned
- 2018-02-02 AU AU2018214208A patent/AU2018214208A1/en active Pending
- 2018-02-02 KR KR1020197025298A patent/KR20190113870A/en not_active Application Discontinuation
- 2018-02-02 WO PCT/EP2018/052624 patent/WO2018141894A1/en unknown
- 2018-02-02 JP JP2019541726A patent/JP7123063B2/en active Active
- 2018-02-02 SG SG11201905259SA patent/SG11201905259SA/en unknown
- 2018-02-02 EP EP18704923.4A patent/EP3577137A1/en active Pending
- 2018-02-02 CN CN201880009856.1A patent/CN110382537B/en active Active
- 2018-02-02 MX MX2019007984A patent/MX2019007984A/en unknown
- 2018-02-02 BR BR112019013648A patent/BR112019013648A2/en unknown
- 2018-02-02 CA CA3050988A patent/CA3050988A1/en active Pending
-
2019
- 2019-06-12 ZA ZA2019/03796A patent/ZA201903796B/en unknown
- 2019-07-31 IL IL268401A patent/IL268401A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2018214208A1 (en) | 2019-07-11 |
JP2020505929A (en) | 2020-02-27 |
ZA201903796B (en) | 2022-11-30 |
EP3577137A1 (en) | 2019-12-11 |
KR20190113870A (en) | 2019-10-08 |
US20190352429A1 (en) | 2019-11-21 |
CN110382537A (en) | 2019-10-25 |
CN110382537B (en) | 2023-07-25 |
JP7123063B2 (en) | 2022-08-22 |
RU2019119391A3 (en) | 2021-05-25 |
MX2019007984A (en) | 2019-10-15 |
BR112019013648A2 (en) | 2020-01-21 |
WO2018141894A1 (en) | 2018-08-09 |
CA3050988A1 (en) | 2018-08-09 |
IL268401A (en) | 2019-09-26 |
RU2019119391A (en) | 2021-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
SG11201811640SA (en) | Multispecific antigen binding proteins and methods of use thereof | |
SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201906373VA (en) | Chemical compounds as inhibitors of interleukin-1 activity | |
SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
SG11201804915RA (en) | Methods for treating huntington's disease | |
SG11201810970WA (en) | Anti-egfr antibody drug conjugates | |
SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
SG11201408536WA (en) | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201906947SA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201408056YA (en) | Fire suppression systems, devices, and methods | |
SG11201807720TA (en) | Methods and systems for determining antibiotic susceptibility | |
SG11201908678XA (en) | Methods and compositions for reduction of immunogenicity | |
SG11201908091QA (en) | Aqueous anti-pd-l1 antibody formulation | |
SG11201908456VA (en) | Linker units and molecular constructs comprising same | |
SG11201903602RA (en) | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody | |
SG11201810429UA (en) | Anti-cd19 antibody formulations |